FDA Approval for Wegovy: The U.S. FDA granted accelerated approval for Novo Nordisk's Wegovy to treat metabolic-associated steatohepatitis (MASH) in adults with liver fibrosis, making it the first GLP-1 therapy approved for this condition.
Positive Trial Results: The approval was based on the ESSENCE trial, where Wegovy showed significant improvement in liver fibrosis and inflammation compared to placebo, with immediate availability in the U.S. alongside diet and exercise recommendations.
Market Impact: Following the approval, Novo Nordisk's stock rose about 7%, while competitor Madrigal Pharmaceuticals saw a decline in shares due to perceived competitive threats from Wegovy, which could potentially unlock a $30 billion market.
Future Prospects: Analysts have a Moderate Buy consensus on NVO stock, with expectations of continued growth as Novo seeks to expand Wegovy's use beyond weight loss into liver care, with further trials and international filings underway.
NVO
$48.475+Infinity%1D
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 48.960
Low
47.00
Averages
57.37
High
70.00
Current: 48.960
Low
47.00
Averages
57.37
High
70.00
HSBC
Hold
maintain
$47 -> $54
2025-12-10
Reason
HSBC
Price Target
$47 -> $54
2025-12-10
maintain
Hold
Reason
HSBC raised the firm's price target on Novo Nordisk to $54 from $47 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
Argus
Buy -> Hold
downgrade
2025-12-08
Reason
Argus
Price Target
2025-12-08
downgrade
Buy -> Hold
Reason
Argus downgraded Novo Nordisk to Hold from Buy. The company has seen the market share of its GLP-1 drugs - Wegovy and Ozempic - decline in recent quarters and has also agreed to lower prices of these drugs in the U.S. markets, the analyst tells investors in a research note. Novo Nordisk will also soon face the entrance of generic versions of these products in certain international markets while, concurrently, some of the company's key clinical trials have "failed to impress", with the recent trials of semaglutide not confirming superiority relative to placebo in reduction of Alzheimer's disease progression, the firm added.
Argus
Buy
to
Hold
downgrade
2025-12-08
Reason
Argus
Price Target
2025-12-08
downgrade
Buy
to
Hold
Reason
Argus downgraded Novo Nordisk to Hold from Buy.
JPMorgan
Richard Vosser
Overweight
downgrade
2025-12-08
Reason
JPMorgan
Richard Vosser
Price Target
2025-12-08
downgrade
Overweight
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Novo Nordisk to DKK 350 from DKK 500 and keeps an Overweight rating on the shares.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
